{"disease":{"id":"muscular-atrophy","name":"muscular atrophy"},"drugs":{"marketed":[{"drug_id":"risdiplam","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evrysdi","generic_name":"RISDIPLAM","company_name":"Roche","drug_phase":"marketed","molecular_target":"","drug_class":"Survival of Motor Neuron 2 Splicing Modifier [EPC]","quality_score":10,"revenue":"2300","mechanism":"Evrysdi works by increasing the production of survival motor neuron protein."},{"drug_id":"zolgensma","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zolgensma","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":"925","mechanism":null},{"drug_id":"nusinersen","indication_name":"Spinal muscular atrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spinraza","generic_name":"NUSINERSEN","company_name":"Biogen Idec","drug_phase":"marketed","molecular_target":"","drug_class":"Survival Motor Neuron-2-directed RNA Interaction [EPC]","quality_score":40,"revenue":null,"mechanism":"Spinraza works by binding to a specific genetic sequence to increase production of a protein that helps maintain muscle function."},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Spinal Muscular Atrophy (SMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":10,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":116,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06027385","title":"Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":300000,"lead_sponsor_name":"Cystinose Stiftung","has_results":false},{"nct_id":"NCT03217578","title":"Neonatal Spinal Muscular Atrophy (SMA) Screening","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","has_results":false},{"nct_id":"NCT03554343","title":"Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium","phase":"","overall_status":"COMPLETED","enrollment_count":136339,"lead_sponsor_name":"Centre Hospitalier Régional de la Citadelle","has_results":false},{"nct_id":"NCT05481164","title":"Newborn Screening for Spinal Muscular Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":33568,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT06310421","title":"Spinal Muscular Atrophy Neonatal Screening Program","phase":"","overall_status":"RECRUITING","enrollment_count":11500,"lead_sponsor_name":"IRCCS Burlo Garofolo","has_results":false},{"nct_id":"NCT05237544","title":"Newborn Screening for Spinal Muscular Atrophy (SMA) - a Proof of Principle Study Using Anonymised Blood Spots.","phase":"","overall_status":"COMPLETED","enrollment_count":5065,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT05966038","title":"ALS/MND Natural History Study Data Repository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07403214","title":"A Real-world Study of Disease-modifying Therapy Treatment Outcomes in Patients With Spinal Muscular Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":4805,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07378943","title":"A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":4114,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04010604","title":"A Registered Cohort Study on SMA","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Wan-Jin Chen","has_results":false},{"nct_id":"NCT03555578","title":"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg \"All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)\"","phase":"","overall_status":"RECRUITING","enrollment_count":1890,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05755451","title":"Natural History of SMA","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04177134","title":"French Register of Patients With Spinal Muscular Atrophy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05187260","title":"Antisense Oligonucleotide for Spinal Muscular Atrophy","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT04292574","title":"UK SMA Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT01059240","title":"SMN Copy Number Distribution in Mali, West Africa","phase":"","overall_status":"COMPLETED","enrollment_count":701,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04174157","title":"Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03520179","title":"Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT05042921","title":"Pediatric Spinal Muscular Atrophy (SMA) China Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06978985","title":"Adult SMA Research and Clinical Hub","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Newcastle-upon-Tyne Hospitals NHS Trust","has_results":false},{"nct_id":"NCT07530926","title":"Adrenal& Bone Complications in Paediatric Patients Living With Spinal Muscular Atrophy (SMA)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":550,"lead_sponsor_name":"Sheffield Children's NHS Foundation Trust","has_results":false},{"nct_id":"NCT05768048","title":"Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07467187","title":"Invasive Home Ventilation in Denmark","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05232929","title":"Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":404,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT05866939","title":"Development of a Multidisciplinary Network for Clinical and Laboratory Research for SMA","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05663008","title":"Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Dublin, Trinity College","has_results":false},{"nct_id":"NCT05475691","title":"Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America","phase":"","overall_status":"UNKNOWN","enrollment_count":361,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT02594124","title":"A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":292,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05115110","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05769465","title":"MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy","phase":"","overall_status":"UNKNOWN","enrollment_count":247,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05626855","title":"Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":238,"lead_sponsor_name":"Scholar Rock, Inc.","has_results":false},{"nct_id":"NCT02908685","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07474311","title":"A Real-World Study of Clinical Use of Available Treatments for Pediatric Patients With Spinal Muscular Atrophy","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05618379","title":"Adult Spinal Muscular Atrophy (SMA) China Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07223489","title":"Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Medstar Health Research Institute","has_results":false},{"nct_id":"NCT04967716","title":"Genetics of Charcot-Marie-Tooth Dystrophy and Related Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05156320","title":"Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Scholar Rock, Inc.","has_results":false},{"nct_id":"NCT05335876","title":"Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03032172","title":"A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06178393","title":"Real-World Use of Novel Treatments in Patients With Spinal Muscular Atrophy (SMA): A Multi-Site Retrospective Chart Review of Pediatric SMA Patients Outside of the United States","phase":"","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04404764","title":"Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT05366465","title":"Quality of Life and Participation of the Adult with Spinal Muscular Atrophy in France","phase":"","overall_status":"COMPLETED","enrollment_count":149,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03709784","title":"Spinraza in Adult Spinal Muscular Atrophy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":148,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT04089566","title":"Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT04718181","title":"Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02628743","title":"A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05089656","title":"Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02292537","title":"A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT02193074","title":"A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":122,"lead_sponsor_name":"Biogen","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}